SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

Effective treatment of mitochondrial myopathy by nicotinamide riboside, a vitamin B3.

Khan, NA; Auranen, M; Paetau, I; Pirinen, E; Euro, L; Forsström, S; Pasila, L; Velagapudi, V; Carroll, CJ; Auwerx, J; et al. Khan, NA; Auranen, M; Paetau, I; Pirinen, E; Euro, L; Forsström, S; Pasila, L; Velagapudi, V; Carroll, CJ; Auwerx, J; Suomalainen, A (2014) Effective treatment of mitochondrial myopathy by nicotinamide riboside, a vitamin B3. EMBO Mol Med, 6 (6). pp. 721-731. ISSN 1757-4684 https://doi.org/10.1002/emmm.201403943
SGUL Authors: Carroll, Christopher John

[img]
Preview
PDF Published Version
Available under License Creative Commons Attribution.

Download (3MB) | Preview

Abstract

Nutrient availability is the major regulator of life and reproduction, and a complex cellular signaling network has evolved to adapt organisms to fasting. These sensor pathways monitor cellular energy metabolism, especially mitochondrial ATP production and NAD(+)/NADH ratio, as major signals for nutritional state. We hypothesized that these signals would be modified by mitochondrial respiratory chain disease, because of inefficient NADH utilization and ATP production. Oral administration of nicotinamide riboside (NR), a vitamin B3 and NAD(+) precursor, was previously shown to boost NAD(+) levels in mice and to induce mitochondrial biogenesis. Here, we treated mitochondrial myopathy mice with NR. This vitamin effectively delayed early- and late-stage disease progression, by robustly inducing mitochondrial biogenesis in skeletal muscle and brown adipose tissue, preventing mitochondrial ultrastructure abnormalities and mtDNA deletion formation. NR further stimulated mitochondrial unfolded protein response, suggesting its protective role in mitochondrial disease. These results indicate that NR and strategies boosting NAD(+) levels are a promising treatment strategy for mitochondrial myopathy.

Item Type: Article
Additional Information: This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. © 2014 The Authors. Published under the terms of the CC BY license
Keywords: NAD+, mitochondrial myopathy, nicotinamide riboside, treatment, unfolded protein response, Adipose Tissue, Brown, Animals, Energy Metabolism, Forkhead Box Protein O1, Forkhead Transcription Factors, Lipid Metabolism, Liver, Male, Mice, Mice, Inbred C57BL, Mitochondria, Mitochondrial Myopathies, Muscle, Skeletal, NAD, Niacinamide, Sirtuin 1, Unfolded Protein Response, Vitamin B Complex, 06 Biological Sciences, 11 Medical And Health Sciences
SGUL Research Institute / Research Centre: Academic Structure > Molecular and Clinical Sciences Research Institute (MCS)
Academic Structure > Molecular and Clinical Sciences Research Institute (MCS) > Cell Sciences (INCCCS)
Journal or Publication Title: EMBO Mol Med
ISSN: 1757-4684
Language: eng
Dates:
DateEvent
June 2014Published
6 April 2014Published Online
17 March 2014Accepted
Publisher License: Creative Commons: Attribution 4.0
Projects:
Project IDFunderFunder ID
R01 AG043930NIA NIH HHSUNSPECIFIED
R01 HL106511NHLBI NIH HHSUNSPECIFIED
R01AG043930NIA NIH HHSUNSPECIFIED
R01HL106511-01ANHLBI NIH HHSUNSPECIFIED
PubMed ID: 24711540
Go to PubMed abstract
URI: https://openaccess.sgul.ac.uk/id/eprint/109276
Publisher's version: https://doi.org/10.1002/emmm.201403943

Actions (login required)

Edit Item Edit Item